Kite Pharma, Inc. (NASDAQ: KITE) to Ring The NASDAQ Stock

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Kite Pharma, Inc. (NASDAQ: KITE) to Ring The NASDAQ Stock Market Closing Bell

ADVISORY, June 20, 2014 (GLOBE NEWSWIRE) --

What:

Kite Pharma, Inc. (Nasdaq: KITE ), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, will visit the NASDAQ MarketSite in Times Square in celebration of its recent initial public offering.

In honor of the occasion, Arie Belldegrun, M.D., FACS - Chairman, President & CEO will ring the Closing Bell.

Where:

NASDAQ MarketSite – 4 Times Square – 43 rd & Broadway – Broadcast Studio

When:

Monday, June 23, 2014 – 3:45 p.m. to 4:00 p.m. ET       

Kite Pharma, Inc. Contact:
Justin Jackson
(212) 213-0006
jjackson@burnsmc.com

NASDAQ MarketSite:
Christine Barna
(646) 441-5310
Christine.Barna@nasdaqomx.com

Feed Information:

Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
FEC 3/4
SR 13.235
DR 18.295411
MOD 4:2:0
DVBS QPSK

Social Media:

For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ .

For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq .

For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx .

For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/ .

Webcast:

A webcast of the NASDAQ Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx .

Photos:

To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.

About Kite Pharma, Inc. (Nasdaq: KITE ):

Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on eACT™ designed to restore the immune system's ability to recognize and eradicate tumors. In partnership with the NCI Surgery Branch through a Cooperative Research and Development Agreement (CRADA), Kite is advancing a pipeline of proprietary eACT™ product candidates, both CAR (chimeric antigen receptor) and TCR (T cell receptor) products, directed to a wide range of cancer indications. Kite's management team has a proven track record of building successful biotechnology companies and successfully developing novel immunotherapies and other oncology treatments. Kite is based in Santa Monica, CA.

About NASDAQ OMX Group

NASDAQ OMX (Nasdaq: NDAQ ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com .

-NDAQA-

Scroll down for more posts ▼

Top 10 Most Recent News Articles

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 185

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
BETR's Slide: Investors Face Big Losses, Leadership Shift

Updated Category News Views 170

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 234

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
Fluence Energy Faces Leadership Departures Amid Legal Woes

Updated Category News Views 155

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

Continue Reading
Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Updated Category News Views 143

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 321

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 139

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Advanta's Game-Changer: Acquiring Misr Hytech to Expand in Africa

Updated Category News Views 249

Advanta's Strategic Move into Africa Alright, let's cut to the chase. Advanta is making a big splash with its acquisition of Misr Hytech, a move that's going to shake things up in Africa's agricultural sector. This isn't just another merger to gloss over with your morning coffee. We're talking about a deal that's supposed to wrap up by January 31, 2027, bringing together...

Continue Reading
CARsgen's CAR-T Breakthrough on China's Insurance List

Updated Category News Views 230

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Continue Reading
Luvme Hair Offers Wig Variety for Winter Fashion

Updated Category News Views 313

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

Continue Reading

Top 5 Most Recently Viewed Articles

Healthcare Realty Trust's Q4 Highlights and Dividend Update

Updated Category News Views 112

Healthcare Realty Trust Quarterly Results Overview Healthcare Realty Trust Incorporated (NYSE: HR) has reported its fourth quarter results for the year 2024, highlighting significant developments in its operations and financial performance. The company recorded a net (loss) income attributable to common stockholders of $(106.8) million, or $(0.31) per diluted share,...

Continue Reading
BGL's Strategic Move: Selling Western Botanicals to Riverside

Updated Category News Views 322

Brown Gibbons Lang & Company (BGL) has just sealed the deal on a significant sale—Western Botanicals, a prominent player in the Vitamins, Minerals, and Supplements (VMS) contract development and manufacturing space, is headed to The Riverside Company. Now this isn’t just another corporate shuffle; it's BGL’s third foray into the CDMO subsector and marks their fourth...

Continue Reading
High Arctic Energy Services Reports Second Quarter 2025 Success

Updated Category News Views 225

High Arctic Energy Services Reports Strong Second Quarter Results High Arctic Energy Services Inc. (TSX: HWO), a noted energy services provider, has recently shared its financial results for the second quarter of 2025, highlighting a continued commitment to operational excellence amid challenging market conditions. 2025 Second Quarter Performance Overview The company...

Continue Reading
DXC Technology Investors Notified of Securities Class Action

Updated Category News Views 45

DXC Technology Class Action Notice for Shareholders The Gross Law Firm has released an important notice for shareholders of DXC Technology Company (NYSE: DXC). This notice is aimed at individuals who acquired shares during the specified class period. Shareholders are encouraged to reach out to the firm if they are interested in being considered for the role of lead...

Continue Reading
Manulife's $750M US Offering: Risky or Strategic?

Updated Category News Views 50

Manulife: Debuting $750M in Subordinated Notes When it comes to Manulife's latest move, it's all about the numbers. They've priced a U.S. public offering of a meaty $750 million in subordinated notes at an enticing 6.146% interest rate. That's no pocket change, folks, and it highlights a strategy or a gamble, depending on your view. But here's the kicker: these notes may...

Continue Reading